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1932The NCDR (National Cardio-
vascular Data Registry) comprises
7 distinct quality measurement
and improvement programs de-
veloped by the American Col-
lege of Cardiology Foundation
(ACCF), often in collaboration
with partner organizations. The
mission of the NCDR is to
improve the quality of cardio-
vascular patient care by mea-
suring adherence to performance
metrics, providing direct feed-back to participating sites together with knowledge and tools
to improve performance; implementing quality initiatives;
and supporting research that improves patient care and
outcomes. The primary aim of the registries is to optimize
the management and outcomes of patients with cardiovas-
cular disease by collecting and reporting data to improve the
quality and safety of care through the provision of risk-
adjusted outcomes for benchmarking and novel quality
improvement methods. The ﬁrst NCDR program, the
CathPCI Registry, was launched in 1998 and has collected
detailed clinical information on nearly 10 million coronary
angiography and percutaneous coronary intervention (PCI)
procedures performed in the United States (1). The NCDR
has subsequently expanded to include 6 additional registries
across the spectrum of cardiovascular disease.
The process for developing the core registry datasets
follows an established methodology for creating and
implementing speciﬁc data standards. Committees of
experts from multiple disciplines, reﬂecting both quality
improvement and research priorities, identify key data
elements and metrics to assess the quality of care for
a speciﬁed patient population. These data elements and
deﬁnitions are then subjected to review and iterative
reﬁnement, which includes a ranking process, a public
comment period, and alpha and beta site review to establish
feasibility, until consensus is reached on the ﬁnal data
elements and deﬁnitions. Upon completion of the ﬁnal
dataset and data dictionary, a data collection form isand maintain quality measures, reports stock
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current clinical practice and ongoing scientiﬁc relevance.
Data are collected by participants for entry into central data
repositories maintained by the ACCF. The NCDR applies
a comprehensive data quality program to enhance the
validity and reliability of registry data (2). Key performance
metrics are supplied to all participants on a quarterly basis
accompanied by an explanation of the benchmarking
methodology used to facilitate comparison of the outcomes of
one institution with results nationally.
The objective of this report is to provide a description and
overview of the patient populations, participating centers, and
patterns of care from the 5 NCDR registries for which
comprehensive data from 2011 are available. Two recently
initiated registries (Improving Pediatric and Adult Congen-
ital Treatment, and the Society of Thoracic Surgeons/
American College of Cardiology Transcatheter Valve
Therapy Registries) are not included. This report primarily
focuses on data from 2011, while also illustrating temporal
trends in some patient and care characteristics. Where
available, the report highlights similar data elements and
outcomes across the registries.
The NCDR ACTION Registry–GWTG
The ACTION (Acute Coronary Treatment and Interven-
tion Outcomes Network) Registry–GWTG (Get With
The Guidelines) is sponsored by the ACCF in conjunction
with the American Heart Association, with partnering
support from the Society of Cardiovascular Patient Care, The
American College of Emergency Physicians, and The
Society of Hospital Medicine (3). The ACTION Registry–
GWTG was designed to assess the characteristics, treat-
ments, and outcomes of acute myocardial infarction (AMI)
patients (either ST-segment elevation myocardial infarction
or non–ST-segment elevation myocardial infarction).
Eligible patients are those older than 18 years of age hospi-
talized with a diagnosis of AMI who have acute ischemic
symptoms within 24 h of presentation. Patients admitted for
other conditions who subsequently develop AMI during
hospital stay are not included (Figs. 1 to 6, Tables 1 to 6).Sanoﬁ-Aventis, Janssen Pharmaceuticals, Merck, Regeneron, and Daiichi-Sankyo.
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Figure 1
ACTION Registry–GWTG Participating Hospital/Center Distribution (2011) (Not Shown: Alaska 1 Site, Hawaii 2 Sites,
Puerto Rico, 1 Site)
Figure 2
ACTION Registry–GWTG Processes of Care Metrics:
Cardiac Procedures and Revascularization Strategies
Among Eligible Patients (2011)
CABG ¼ coronary artery bypass grafting; Cath ¼ catheterization; NSTEMI ¼ non–
ST-segment elevation myocardial infarction; PCI ¼ percutaneous coronary inter-
vention; STEMI ¼ ST-segment elevation myocardial infarction.
Figure 3
ACTION Registry–GWTG Processes of Care Metrics:
Anticoagulant/Antiplatelet Dosing Errors by MI Type
(2011)
Refer to the Online Appendix for deﬁnitions. *Infusion (>15 U/kg/h) or bolus
(>70 U/kg); #initial dose (>1.05 mg/kg). MI ¼ myocardial infarction;
GP ¼ glycoprotein; LMWH ¼ low-molecular-weight heparin; UFH ¼ unfractionated
heparin; other abbreviations as in Figure 3.
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Figure 4
ACTION Registry–GWTG Processes of Care Metrics:
Temporal Trends in Timeliness of Reperfusion Use for
STEMI Patients (2008 to 2011)
Refer to the Online Appendix for deﬁnitions. D2B ¼ door-to-balloon time;
D2Needle ¼ door-to-needle time; STEMI ¼ ST-segment elevation myocardial
infarction.
Figure 6
ACTION Registry–GWTG Outcomes Metrics:
In-Hospital Outcomes by MI Type (2011, Unadjusted)
Abbreviations as in Figures 2 and 3.
Figure 5
ACTION Registry–GWTG Processes of Care Metrics:
Temporal Trends in Median Time to Primary PCI for
STEMI Patients (2008 to 2011)
Abbreviations as in Figure 2.
Table 1
ACTION Registry–GWTG Population Characteristics:
Patient Demographic Characteristics According to
MI Type (2011)
All
(n ¼ 119,967)
STEMI
(n ¼ 46,791)
NSTEMI
(n ¼ 73,176)
Female 35.3% 29.8% 38.8%
Age
Mean age (yrs) 65 62 67
<55 25.1% 31.8% 20.9%
55–<65 26.4% 30.0% 24.1%
65–<80 31.1% 26.9% 33.9%
80 17.4% 11.4% 21.2%
Race
White 85.5% 86.8% 84.7%
Black/African-American 11.5% 10.0% 12.4%
Asian 1.8% 1.9% 1.7%
American Indian/Alaskan 0.6% 0.6% 0.5%
Hawaiian/Paciﬁc Islander 0.2% 0.2% 0.2%
Hispanic or Latino ethnicity 4.9% 5.1% 4.8%
Values are %.
MI ¼myocardial infarction; NSTEMI ¼ non–ST-segment elevation myocardial infarction; STEMI ¼
ST-segment elevation myocardial infarction.
Table 2
ACTION Registry–GWTG Population Characteristics:
Patient Medical History and Risk Factors According to
MI Type (2011)
All
(n ¼ 119,967)
STEMI
(n ¼ 46,791)
NSTEMI
(n ¼ 73,176)
History and risk factors
Diabetes mellitus 32.5% 24.4% 37.7%
Prior MI 25.0% 18.5% 29.1%
Prior heart failure 12.9% 5.4% 17.7%
Prior PCI 24.1% 19.8% 26.9%
Prior CABG 14.0% 6.6% 18.7%
Prior stroke 7.9% 5.0% 9.8%
Prior PAD 9.5% 5.7% 12.0%
BMI, kg/m2 29.6  5.9 29.2  5.6 29.8  6.1
Underweight (<18.5) 0.4% 0.4% 0.4%
Normal weight
(18.5–24.9)
21.4% 21.5% 21.4%
Overweight (25–29.9) 37.3% 39.2% 36.1%
Obese (30) 40.8% 38.9% 42.1%
Values % or mean  SD.
BMI ¼ body mass index; CABG ¼ coronary artery bypass grafting; PAD ¼ peripheral arterial
disease; PCI ¼ percutaneous coronary intervention; other abbreviations as in Table 1.
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Table 3
ACTION Registry–GWTG Participating Hospital/
Center Characteristics (2011)
Number of hospitals 567
Hospital type
Private/community 88.0%
Government 2.3%
University 9.7%
Hospital location
Rural 18.1%
Urban 48.8%
Suburban 33.1%
Teaching hospital 39.1%
Certiﬁed beds 350  218
On-site services
No catheterization lab services on-site 20.4%
Diagnostic catheterization performed on-site 79.6%
Diagnostic catheterization and PCI performed on-site 75.9%
Cardiac surgery, diagnostic catheterization,
and PCI all performed on-site
64.3%
Values are % or mean  SD.
PCI ¼ percutaneous coronary intervention.
Table 4
ACTION Registry–GWTG Processes of Care Metrics:
Composite Metric Performance (2011)
Percentiles
10th 50th 90th
Overall AMI performance composite 84.3% 94.4% 98.6%
Overall defect free care 22.9% 72.2% 92.3%
STEMI performance composite 86.6% 96.1% 99.3%
NSTEMI performance composite 81.2% 93.3% 98.5%
Acute AMI performance composite 90.4% 96.0% 98.9%
Discharge AMI performance composite 77.9% 93.9% 99.1%
Values are n or %. Participant level. Refer to the Online Appendix for deﬁnitions.
AMI ¼ acute myocardial infarction; other abbreviations as in Table 1.
Table 6
ACTION Registry–GWTG Processes of Care Metrics:
AMI Institutional Quality Metrics (2011)
n
Percentiles
10th 50th 90th
ECG within 10 min of arrival 38,243 41.2% 64.4% 82.8%
Acute ADP receptor inhibitor
therapy among STEMI
patients
24,540 81.9% 94.7% 100.0%
Acute anticoagulant agent
among NSTEMI patients
30,145 78.6% 90.3% 100.0%
Revascularized patients
discharged on ADP
receptor inhibitors
65,807 83.7% 93.4% 100.0%
ADP receptor inhibitors
prescribed at discharge for
medically treated AMI
patients
13,612 33.9% 55.3.% 78.9%
Aldosterone blocking agents
for eligible patients
(LVSD with either diabetes
mellitus or heart failure)
at discharge
1,634 0.4% 7.8% 33.9%
LDL-cholesterol assessment 86,582 64.1% 83.1% 94.8%
Aspirin at arrival for all
patients
103,335 94.0% 98.9% 100.0%
Values are n or %. Participant level. Refer to the Online Appendix for other deﬁnitions.
AMI ¼ acute myocaridal infarction; LDL ¼ low-density lipoprotein.
Table 5
ACTION Registry–GWTG Processes of Care Metrics:
AMI Institutional Performance Measures (2011)
Percentiles
10th 50th 90th
Aspirin at arrival (excluding patients
transferred in and out)
93.8% 99.1% 100.0%
Aspirin prescribed at discharge 94.2% 98.9% 100.0%
Beta-blocker prescribed at discharge 89.2% 97.5% 100.0%
Statin prescribed at discharge 95.1% 98.9% 100.0%
Evaluation of LVSF 87.2% 95.6% 100.0%
ACE-I or ARB for LVSD at discharge 66.7% 89.0% 100.0%
Adult smoking cessation advice
counseling
93.0% 100.0% 100.0%
Cardiac rehabilitation patient referral
from an inpatient setting
9.8% 83.8% 99.2%
Median D2B time for non-transferred
patients (min)
72.1 60.8 48.9
Median D2B time for transferred patients
(min)
187.1 113.3 84.5
Median door-in-door-out time for
transferred patients (min)
89.3 49.3 30.9
Participant level. Refer to the Online Appendix for other deﬁnitions.
ACE-I ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor block; D2B ¼ door-to-balloon
time; LVSD ¼ left ventricular systolic dysfunction; LVSF ¼ left ventricular systolic function.
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The CathPCI Registry is sponsored by ACCF in
conjunction with the Society for Cardiovascular Angiog-
raphy and Interventions. The CathPCI Registry was
designed to create a national surveillance system to assess
the characteristics, treatments, and outcomes of patients
with coronary heart disease who undergo procedures in
cardiac catheterization laboratories. The CathPCI Registry
does not mandate data collection for all angiographies,
although it does require inclusion of all consecutive PCIs.
Approximately two-thirds of participating sites submit
some data on both diagnostic catheterization and PCI; and
one-third submits data for PCI only (4). Eligible patients
are adults (18 years of age and older) who undergo a diag-
nostic cardiac catheterization and/or PCI. For diagnostic
catheterization, eligible procedures include catheterization
with the passage of a catheter into the aortic root for
pressure measurements and/or angiography and can include
left ventricular pressure measurements, left ventricular
angiography, coronary angiography, and coronary artery
bypass angiography. For PCI, eligible procedures include
those that involve passage or attempted passage of a device
across 1 or more coronary lesion(s) for the purpose of
increasing the intraluminal diameter of the vessel and/or
restoring or improving circulation (Figs. 7 to 13, Tables
7 to 10).
Figure 7
CathPCI Registry Participating Hospital/Center Distribution (2011) (Not Shown: Alaska 4 Sites, Hawaii 6 Sites,
U.S. Virgin Islands 1 Site
Figure 8
CathPCI Registry Processes of Care Metrics:
Temporal Trends in Median Time to Immediate PCI for
STEMI Patients (2009 to 2011)
Refer to the Online Appendix for deﬁnitions. Abbreviations as in Figure 2.
Figure 9
CathPCI Registry Processes of Care Metrics:
Temporal Trends in Proportion of STEMI Patients
Receiving Immediate PCI Within 90 Min
(2009 to 2011)
Refer to the Online Appendix for deﬁnitions. Abbreviations as in Figure 2.
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Figure 10
CathPCI Registry Processes of Care Metrics:
Temporal Trends in Discharge Medications in PCI
Patients (2009 to 2011)
Refer to the Online Appendix for deﬁnitions. PCI ¼ percutaneous coronary
intervention.
Figure 11
CathPCI Registry Processes of Care Metrics:
Temporal Trends in Arterial Access Site
(2009 to 2011)
Limited to percutaneous coronary intervention patients only.
Figure 12
CathPCI Registry Outcomes Metrics: Temporal
Trends in PCI In-Hospital Risk Adjusted Mortality
(2009 to 2011)
Limited to PCI patients only. Refer to the Online Appendix for deﬁnitions. Abbrevia-
tions as in Figure 2.
Figure 13
CathPCIRegistryOutcomesMetrics: Temporal Trends
in PCI Outcome Metrics (2009 to 2011)
Unadjusted; limited to PCI patients only. Refer to the Online Appendix for deﬁni-
tions. Abbreviations as in Figure 2.
Table 7
CathPCI Registry Population Characteristics: Patient Demographic Characteristics
(2011)
N 632,557
Female 32.4%
Age (yrs)
Mean age 65
<55 21.1%
55–<65 28.1%
65–<80 38.6%
80 12.2%
Race
White 87.7%
Black/African-American 8.3%
Asian 2.4%
American Indian/Alaskan 0.6%
Hawaiian/Paciﬁc Islander 0.2%
Hispanic or Latino ethnicity 5.2%
Limited to percutaneous coronary intervention patients only.
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Table 9
CathPCI Registry Participating Hospital/Center
Characteristics (2011)
Number of hospitals 1,337
Hospital type
Private/community 90.4%
Government 1.6%
University 8.1%
Hospital location
Rural 18.1%
Urban 46.1%
Suburban 35.8%
Teaching hospital 38.5%
Certiﬁed beds 336  211
PCI procedures, n
0–10 46
11–200 292
201–400 332
401–600 250
601–1,000 246
1001–2,000 139
2001þ 20
Values are n, %, or mean  SD.
PCI ¼ percutaneous coronary intervention.
Table 10
CathPCI Registry Processes of Care Metrics:
PCI Appropriate Use Criteria Metrics (2011)
For classiﬁable patients with ACS (excludes unclassiﬁable
patients)
n ¼ 421,760
Proportion of evaluated PCI procedures that were appropriate 99.1%
Proportion of evaluated PCI procedures that were of uncertain
appropriateness
0.2%
Proportion of evaluated PCI procedures that were
inappropriate
0.7%
For classiﬁable patients without ACS (excludes unclassiﬁable
patients)
n ¼ 139,104
Proportion of evaluated PCI procedures that were appropriate 52.8%
Proportion of evaluated PCI procedures that were of uncertain
appropriateness
37.3%
Proportion of evaluated PCI procedures that were
inappropriate
9.9%
Values are n or %. Limited to PCI patients only, using 2009 Appropriate Use Criteria. Refer to the
Online Appendix for other deﬁnitions.
ACS ¼ acute coronary syndromes; PCI ¼ percutaneous coronary intervention.
Table 8
CathPCI Registry Population Characteristics:
Patient Medical History and Risk Factors (2011)
History and risk factors
Diabetes mellitus 36.8%
Prior MI (>7 days) 30.2%
Heart failure within past 2 weeks 12.1%
Prior PCI 40.8%
Prior CABG 18.4%
Status of PCI
Elective 42.6%
Urgent 39.1%
Emergent 17.9%
Salvage 0.3%
BMI, kg/m2 (excluding BMIs >50.0) 30.3  6.3
Underweight (<18.5) 0.4%
Normal weight (18.5–24.9) 18.6%
Overweight (25.0–29.9) 35.1%
Obese (30.0) 45.9%
Values are % or mean  SD. Limited to PCI patients only.
BMI ¼ body mass index; other abbreviations as in Tables 1 and 2.
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The CARE (Carotid Artery Revascularization and Endar-
terectomy) Registry is sponsored by ACCF in conjunction
with the Society for Cardiovascular Angiography and
Interventions, Society of Interventional Radiology, Amer-
ican Academy of Neurology, American Association of
Neurological Surgeons/Congress of Neurological Surgeons,
Society for Vascular Medicine, and Society of Vascular
and Interventional Neurology. The CARE Registry was
designed to create a national surveillance system to assess
the prevalence, demographic data, management, and
outcomes of patients undergoing carotid stenting or carotid
endarterectomy. Eligible patients are adults undergoing
carotid artery stenting (CAS) and/or carotid endarterec-
tomy (CEA) for the purpose of stroke prevention (Figs.
14 to 19, Tables 11 to 13).Figure 14
CARE Registry Population Characteristics:
Temporal Trends in Procedures With Patients at
High Surgical Risk (2008 to 2011)
Refer to the Online Appendix for deﬁnitions. CAS ¼ cartoid artery stenting;
CEA ¼ carotid endarterectomy.
Figure 15 CARE Registry Participating Hospital/Center Distribution (2011)
Figure 16
CARE Registry Processes of Care Metrics: Temporal
Trends in Any Follow-Up Performed Within 30 Days
After the Procedure (2008 to 2011)
Refer to the Online Appendix for deﬁnitions. Abbreviations as in Figure 14.
Figure 17
CARE Registry Processes of Care Metrics:
Temporal Trends in Proportion of Patients Receiving
Post-Procedure and/or 30-Day Follow-Up
NIHSS Assessment (2008 to 2011)
NIHSS ¼ National Institutes of Health Stroke Scale; other abbreviations as in
Figure 14.
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Figure 18
CARE Registry Outcomes Metrics: Temporal Trends
in Incidence of Death or Stroke for Symptomatic and
Asymptomatic CAS Patients (2008 to 2011,
Unadjusted)
Patients undergoing CAS were overall a higher-risk population than those under-
going CEA. For example, in 2011, 74.7% of patients undergoing CAS were
considered high surgical risk compared with 47.6% of those undergoing CEA.
Unadjusted outcomes of CAS and CEA are not suitable for direct comparison.
Refer to the Online Appendix for deﬁnitions. Abbreviations as in Figure 14.
Figure 19
CARE Registry Outcomes Metrics: Temporal Trends
in Incidence of Death or Stroke for Symptomatic and
Asymptomatic CEA Patients (2008 to 2011,
Unadjusted)
Patients undergoing CAS were overall a higher-risk population than those under-
going CEA. For example, in 2011, 74.7% of patients undergoing CAS were
considered high surgical risk compared with 47.6% of those undergoing CEA.
Unadjusted outcomes of CAS and CEA are not suitable for direct comparison.
Refer to the Online Appendix for deﬁnitions. Abbreviations as in Figure 14.
Table 11 CARE Registry Population Characteristics: Patient Demographic Characteristics (2011)
CAS CEA
All CAS
Symptomatic
Patients
Asymptomatic
Patients All CEA
Symptomatic
Patients
Asymptomatic
Patients
n 2,842 1,183 1,659 2,092 729 1,363
Female 38% 39% 38% 40% 39% 41%
Age
Mean age, yrs 69 69 70 70 70 70
<55 7.1% 9.7% 5.3% 6.4% 9.1% 5.0%
55–<65 20.4% 20.4% 20.4% 18.5% 18.1% 18.7%
65–<80 51.9% 48.5% 54.4% 54.5% 51.6% 56.1%
80 18.2% 18.9% 17.7% 19.0% 19.6% 18.6%
Race
White 89.7% 89.3% 89.9% 92.5% 91.5% 93.1%
Black/African-American 4.2% 4.6% 4.0% 3.8% 4.8% 3.2%
Asian 1.0% 0.9% 1.1% 0.3% 0.1% 0.4%
American Indian/Alaskan 0.4% 0.7% 0.1% 0.2% 0.5% 0.1%
Hawaiian/Paciﬁc Islander 0.1% 0.1% 0.1% 0.1% 0.3% 0.1%
Other 2.1% 1.7% 2.5% 1.3% 1.1% 1.4%
Hispanic or Latino ethnicity 4.1% 4.1% 4.0% 3.7% 3.6% 3.7%
CAS ¼ carotid artery stenting; CEA ¼ carotid endarterectomy.
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Table 12 CARE Registry Population Characteristics: Patient Medical History and Risk Factors (2011)
History and Risk Factors
CAS CEA
All CAS Symptomatic Patients Asymptomatic Patients All CEA Symptomatic Patients Asymptomatic Patients
Diabetes mellitus 37.3% 36.0% 38.3% 36.1% 34.4% 37.1%
Prior heart failure 15.3% 14.5% 16.0% 7.7% 7.7% 7.8%
Prior PAD 40.9% 37.3% 43.5% 26.5% 23.5% 28.2%
Acute evolving stroke 3.4% 5.2% 2.2% 1.6% 2.9% 0.9%
High surgical risks 74.7% 74.0% 75.1% 47.6% 49.2% 46.7%
CEA restenosis 14.4% 12.3% 15.8% 1.5% 1.9% 1.2%
Difﬁcult surgical access 17.2% 22.2% 14.5%
Contralateral carotid artery occlusion 10.6% 11.3% 10.1% 3.9% 5.3% 3.1%
Prior neck surgery 5.6% 6.3% 5.1% 2.0% 2.3% 1.8%
Previous neck radiation 5.8% 6.7% 5.1% 0.9% 1.0% 0.8%
Tracheostomy present 1.0% 1.1% 1.0% 0.2% 0.4% 0.1%
Severe CAD 29.1% 25.7% 31.5% 20.4% 17.7% 21.8%
Chronic renal disease 2.5% 2.2% 2.8% 1.8% 2.3% 1.5%
Chronic lung disease 26.8% 29.1% 25.3% 21.6% 21.8% 21.5%
EF 30 10.1% 8.8% 11.0% 3.1% 2.9% 3.1%
CCS class III/IV angina 5.5% 5.8% 5.2% 2.3% 2.6% 2.2%
NYHA functional class III/IV 5.9% 5.7% 6.1% 1.2% 1.0% 1.3%
Urgent cardiac surgery planned 2.5% 1.9% 2.9% 2.8% 3.0% 2.6%
MI <6 weeks 2.0% 2.5% 1.6% 1.4% 1.1% 1.50%
BMI, kg/m2 (excluding BMIs >50.0) 28.2  5.6 28.5  5.5
Underweight (<18.5) 1.0% 0.9%
Normal weight (18.5–24.9) 28.2% 26.6%
Overweight (25.0–29.9) 38.5% 38.6%
Obese (30.0) 32.3% 33.8%
Values are % or mean  SD.
CAD ¼ coronary artery disease; CCS ¼ Canadian Cardiovascular Society; EF ¼ ejection fraction; NYHA ¼ New York Heart Association; other abbreviations as in Tables 2 and 11.
Table 13
CARE Registry Participating Hospital/
Center Characteristics (2011)
Hospitals, n 130
Hospital type
Private/community 89.2%
Government 2.3%
University 8.5%
Hospital location
Rural 17.7%
Urban 44.6%
Suburban 37.7%
Teaching hospital 41.5%
Certiﬁed beds 385  183
Values are n, %, or mean  SD.
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The NCDR ICD Registry is sponsored by the ACCF in
conjunction with the Heart Rhythm Society. In January
2005, the Centers for Medicaid and Medicare Services
(CMS) expanded coverage of implantable cardioverter
deﬁbrillators (ICDs) based on the results of 3 major pub-
lished randomized controlled trials (5). Concurrently, CMS
mandated a national database for Medicare patients
receiving ICDs for primary prevention. In response to this
mandate, the NCDR developed the ICD Registry to assess
the characteristics, care, and outcomes of patients under-
going ICD placement at participating centers to determine
whether the randomized controlled trial ﬁndings could be
applied to the general population and to provide additional
insights on outcomes after ICD insertion in subpopulations
of particular interest (6). Eligible patients for inclusion in the
ICD Registry are all adults and pediatric patients under-
going ICD insertion. The CMS mandates that all Medicare
beneﬁciaries receiving an ICD for primary prevention are
included in the Registry (Figs. 20 to 25, Tables 14 to 16).
Figure 21
ICD Registry Procedure Characteristics:
Implant Procedures Performed (2011)
CMS ¼ Centers for Medicaid and Medicare Services. Figure 22
ICD Registry Procedure Characteristics:
Temporal Trends in Primary and Secondary
Prevention Implantations (2007 to 2011)
Figure 20
ICD Registry Participating Hospital/Center Distribution (2011) (Not Shown: Alaska 2 Sites, Hawaii 6 Sites,
U.S. Virgin Islands 1 Site)
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Figure 25
ICD Registry Processes of Care Metrics:
Temporal Trends in Prescribed Discharge
Medications (2007 to 2011)
All ICD implant patients. *Therapy with ACE-I/ARB and beta-blocker at discharge
following ICD implantation in eligible patients. ACE-I ¼ angiotensin-converting
enzyme inhibitor; ARB ¼ angiotensin receptor blocker; ICD ¼ implantable car-
dioverter deﬁbrillator; LVSD ¼ left ventricular systolic dysfunction; MI ¼ myocardial
infarction.
Figure 24
ICD Registry Processes of Care Metrics: Temporal
Trends in Proportion of Initial Generator Implants for
Primary Prevention That Receive an ICD for Class I,
IIa, and IIb Guideline Indications (2010 Quarter 2 to
2011 Quarter 4)
ICD ¼ implantable cardioverter-deﬁbrillator.
Figure 23
ICD Registry Procedure Characteristics: Temporal
Trends in Device Type Implants (2007 to 2011)
CRT-D ¼ cardiac resynchronization therapy deﬁbrillator.
Table 14
ICD Registry Population Characteristics:
Patient Demographic Characteristics (2011)
All Patients
CMS Primary
Prevention
Non-CMS
Primary
Prevention
All
Secondary
Prevention
Patient procedure
count
139,991 74,015 32,116 33,860
Female 27.4% 27.5% 28.9% 25.9%
Age
Mean age (yrs) 68 72 58 66
<55 15.3% 5.6% 34.1% 18.6%
55–<65 20.7% 10.8% 42.1% 22.1%
65–<70 15.3% 18.9% 7.9% 14.3%
70–<75 15.4% 20.0% 5.7% 14.6%
75–<80 15.1% 20.1% 5.0% 13.7%
80 18.2% 24.6% 5.2% 16.6%
Race
White 84.6% 86.2% 78.7% 86.8%
Black/
African-American 12.8% 11.7% 18.0% 10.5%
Asian 1.4% 1.2% 1.8% 1.6%
American Indian/
Alaskan
0.6% 0.6% 0.8% 0.6%
Hawaiian/Paciﬁc
Islander
0.3% 0.2% 0.3% 0.3%
Hispanic or Latino
ethnicity
5.2% 5.3% 6.3% 4.1%
Values are n or %. Refer to the Online Appendix for other deﬁnitions.
CMS ¼ Centers for Medicaid and Medicare Services.
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Table 15
ICD Registry Population Characteristics: Patient Medical History and Risk Factors
(2011)
History and Risk Factors All Patients
CMS Primary
Prevention
Non-CMS Primary
Prevention
All Secondary
Prevention
Diabetes mellitus 38.0% 41.6% 35.2% 33.0%
Prior MI 50.7% 53.7% 42.0% 52.3%
Heart failure 80.1% 88.3% 82.0% 60.4%
Prior PCI 32.6% 34.9% 28.8% 31.2%
Prior CABG 32.7% 38.3% 22.6% 30.1%
BMI, kg/m2 (excluding BMIs >50.0) 29.2  6.2 28.7  5.9 30.4  6.7 29.1  6.1
Underweight (<18.5) 0.8% 0.9% 0.6% 0.8%
Normal weight (18.5–24.9) 25.1% 27.2% 19.9% 25.2%
Overweight (25–29.9) 35.6% 36.6% 32.9% 35.9%
Obese (30.0) 38.6% 35.3% 46.6% 38.1%
Values are % or mean  SD.
Abbreviations as in Table 2.
Table 16
ICD Registry Participating Hospital/
Center Characteristics (2011)
Hospitals, n 1,435
Hospital type
Private/community 90.2%
Government 2.0%
University 7.8%
Hospital location
Rural 18.5%
Urban 47.7%
Suburban 33.8%
Teaching hospital 37.4%
Certiﬁed beds 346  219
Number of generator procedures
1–25 27.3%
26–50 15.9%
51–100 22.2%
101–150 13.8%
151–250 11.9%
251þ 8.9%
Certiﬁcation of implanting physician
Board certiﬁed clinical cardiac EP/adult
or pediatric EP fellowship
64.7%
Pacemaker/ICD COCATS fellowship/ICD operator
training per HRS ICD implantation guidelines
18.4%
Thoracic/cardiac surgery residency 6.0%
None 10.8%
Values are n, %, or mean  SD.
COCATS ¼ Cardiovascular Medicine Core Cardiology Training; EP ¼ electrophysiology; HRS ¼
Heart Rhythm Society; ICD ¼ implantable cardioverter deﬁbrillator.
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The PINNACLE (Practice INNovation And CLinical
Excellence) Registry is dedicated to the quality improve-
ment of cardiovascular medical care provided in the
outpatient setting (7). The PINNACLE Registry enables
the systematic collection of clinical performance measure-
ment data for patients with coronary artery disease, heart
failure, atrial ﬁbrillation, and hypertension. The selected
outpatient performance measures are endorsed by the ACCF
and American Heart Association and have also been
promoted by the Physician Consortium for Performance
Improvement of the American Medical Association, the
Centers for Medicare and Medicaid Physician Quality
Reporting System program, and the National Quality
Forum. The diseases and conditions measured in the
PINNACLE Registry comprise the vast majority of the
clinical activity of cardiovascular specialists and a substantial
portion of the clinical activity of primary care providers.
The PINNACLE Registry Report includes practice
performance for the individual practice compared with the
national average for all practices in the Registry, for the site
locations within each practice compared with each other
and with the practice average, as well as for individual
physicians compared with each other and with the practice
average (Figs. 26 to 31, Tables 17 to 19).
Figure 26 PINNACLE Registry Participating Practice Distribution (2011)
Figure 27
PINNACLE Registry Processes of Care Metrics:
Temporal Trends in Evidence-Based Therapies for
Coronary Artery Disease in Eligible Patients
(2009 to 2011)
Refer to the Online Appendix for deﬁnitions. Abbreviations in Figure 25.
Figure 28
PINNACLE Registry Processes of Care Metrics:
Temporal Trends in Evidence-Based Therapies for
Heart Failure With Left Ventricular Systolic
Dysfunction in Eligible Patients (2009 to 2011)
Refer to the Online Appendix for deﬁnitions. Abbreviations as in Figure 25.
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Figure 29
PINNACLE Registry Processes of Care Metrics:
Temporal Unadjusted Trends in Chronic
Anticoagulation Therapy for Atrial Fibrillation/
Flutter in Eligible Patients (2009 to 2011)
Refer to the Online Appendix for deﬁnitions.
Figure 30
PINNACLE Registry Processes of Care Metrics:
Temporal Trends in Hypertension Measurement and
Care Planning in Eligible Patients (2009 to 2011)
Refer to the Online Appendix for deﬁnitions.
Table 17
PINNACLE Registry Population Characteristics:
Patient Demographic Characteristics (2011)
Unique patients, n 249,198
Female 47%
Mean age, yrs 66
Race
White 90.0%
Black/African American 7.9%
Asian 0.9%
American Indian/Alaskan 1.2%
Hawaiian/Paciﬁc Islander 0.1%
Hispanic or Latino ethnicity 2.7%
Values are n or %.
Figure 31
PINNACLE Registry Processes of Care Metrics:
SBP Control Groups (2011)
For descriptive-purposes, patients were further classiﬁed into 3 levels of SBP
control:<140, 140 to<160, and160mmHg. Bars represent1 SD. BP¼ blood
pressure; SBP = systolic blood pressure.
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Table 19
PINNACLE Registry Participating Practice
Characteristics (2011)
Practices 74
Sites 406
Providers 1,222
Patient encounters 1,436,328
Values are n.
Table 18
PINNACLE Registry Population Characteristics:
Patient Medical History and Risk Factors (2011)
Mean BP values
Systolic, mm Hg 128  18
Diastolic, mm Hg 74  11
% with BP >140/90 mm Hg, n ¼ 13,388 5.9%
History and risk factors
CAD 56.1%
Heart failure 38.7%
Atrial ﬁbrillation/ﬂutter 23.1%
Hypertension 74.1%
Diabetes mellitus 22.3%
Prior stroke 11.5%
Prior PAD 14.5%
Dyslipidemia 67.5%
Tobacco use
Current 12.7%
Former 40.2%
Never 47.1%
BMI, kg/m2 (excluding BMIs >50.0) 30.5  8.4
Underweight (<18.5) 1.6%
Normal weight (18.5–24.9) 23.0%
Overweight (25.0–29.9) 34.8%
Obese (30.0) 40.6%
BP ¼ blood pressure; CAD ¼ coronary artery disease; other abbreviations as in Table 2.
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The NCDR programs provide unique opportunities to
advance the understanding of the clinical characteristics,
care, and outcomes of patients with cardiovascular disease.
Every year, these programs collect data for a broad range
of patients undergoing cardiovascular procedures or in the
outpatient setting in geographically and structurally diversecare settings. The registry programs are able to characterize
the extent of use of evidence-based cardiovascular therapies
and the outcomes of these patients.Acknowledgments
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